{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:34:15Z","timestamp":1791218055887,"version":"4.1.0"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"23","license":[{"start":{"date-parts":[[2010,8,5]],"date-time":"2010-08-05T00:00:00Z","timestamp":1280966400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s00018-010-0469-5","type":"journal-article","created":{"date-parts":[[2010,8,4]],"date-time":"2010-08-04T23:22:33Z","timestamp":1280964153000},"page":"3947-3960","source":"Crossref","is-referenced-by-count":24,"title":["Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target"],"prefix":"10.1007","volume":"67","author":[{"given":"Eleonore","family":"Fr\u00f6hlich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,8,5]]},"reference":[{"issue":"Suppl 61","key":"469_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2133.146.s61.2.x","volume":"146","author":"TL Diepgen","year":"2002","unstructured":"Diepgen TL, Mahler V (2002) The epidemiology of skin cancer. Br J Dermatol 146(Suppl 61):1\u20136","journal-title":"Br J Dermatol"},{"key":"469_CR2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2133.2004.05708.x","volume":"150","author":"MB Lens","year":"2004","unstructured":"Lens MB, Dawes M (2004) Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 150:179\u2013185","journal-title":"Br J Dermatol"},{"key":"469_CR3","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s11912-000-0025-9","volume":"2","author":"AC Buzaid","year":"2000","unstructured":"Buzaid AC, Anderson CM (2000) The changing prognosis of melanoma. Curr Oncol Rep 2:322\u2013328","journal-title":"Curr Oncol Rep"},{"key":"469_CR4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1046\/j.1365-2230.2000.00692.x","volume":"25","author":"RM MacKie","year":"2000","unstructured":"MacKie RM (2000) Malignant melanoma: clinical variants and prognostic indicators. Clin Exp Dermatol 25:471\u2013475","journal-title":"Clin Exp Dermatol"},{"key":"469_CR5","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/00000658-197011000-00017","volume":"172","author":"A Breslow","year":"1970","unstructured":"Breslow A (1970) Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172:902\u2013908","journal-title":"Ann Surg"},{"key":"469_CR6","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1038\/sj.bjc.6603801","volume":"96","author":"RM MacKie","year":"2007","unstructured":"MacKie RM, Bray C, Vestey J, Doherty V, Evans A, Thomson D, Nicolson M (2007) Melanoma incidence and mortality in Scotland 1979\u20132003. Br J Cancer 96:1772\u20131777","journal-title":"Br J Cancer"},{"issue":"Suppl 6","key":"469_CR7","doi-asserted-by":"crossref","first-page":"vi30","DOI":"10.1093\/annonc\/mdp250","volume":"20","author":"AM Eggermont","year":"2009","unstructured":"Eggermont AM, Testori A, Marsden J, Hersey P, Quirt I, Petrella T, Gogas H, MacKie RM, Hauschild A (2009) Utility of adjuvant systemic therapy in melanoma. Ann Oncol 20(Suppl 6):vi30\u2013vi34","journal-title":"Ann Oncol"},{"key":"469_CR8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bbamcr.2009.09.016","volume":"1803","author":"A Kruger","year":"2010","unstructured":"Kruger A, Kates RE, Edwards DR (2010) Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. Biochim Biophys Acta 1803:95\u2013102","journal-title":"Biochim Biophys Acta"},{"key":"469_CR9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2174\/138920309788922207","volume":"10","author":"M Cudic","year":"2009","unstructured":"Cudic M, Fields GB (2009) Extracellular proteases as targets for drug development. Curr Protein Pept Sci 10:297\u2013307","journal-title":"Curr Protein Pept Sci"},{"key":"469_CR10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/156800909787314002","volume":"9","author":"S Ulisse","year":"2009","unstructured":"Ulisse S, Baldini E, Sorrenti S, D\u2019Armiento M (2009) The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 9:32\u201371","journal-title":"Curr Cancer Drug Targets"},{"key":"469_CR11","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0046-8177(84)80310-X","volume":"15","author":"WH Clark","year":"1984","unstructured":"Clark WH, Elder DE Jr, Guerry DT, Epstein MN, Greene MH, Van Horn M (1984) A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 15:1147\u20131165","journal-title":"Hum Pathol"},{"key":"469_CR12","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1038\/jid.2008.166","volume":"128","author":"JM Grichnik","year":"2008","unstructured":"Grichnik JM (2008) Melanoma, nevogenesis, and stem cell biology. J Invest Dermatol 128:2365\u20132380","journal-title":"J Invest Dermatol"},{"key":"469_CR13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature06489","volume":"451","author":"T Schatton","year":"2008","unstructured":"Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank MH (2008) Identification of cells initiating human melanomas. Nature 451:345\u2013349","journal-title":"Nature"},{"key":"469_CR14","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-21619-5","volume-title":"Pathology of melanocytic nevi and malignant melanoma","author":"R Barnhill","year":"2004","unstructured":"Barnhill R, Piepkorn M, Busam K (2004) Pathology of melanocytic nevi and malignant melanoma. Springer, New York"},{"key":"469_CR15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1034\/j.1600-0625.2003.120201.x","volume":"12","author":"E Kerkela","year":"2003","unstructured":"Kerkela E, Saarialho-Kere U (2003) Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol 12:109\u2013125","journal-title":"Exp Dermatol"},{"key":"469_CR16","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L","volume":"71","author":"S Aznavoorian","year":"1993","unstructured":"Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA (1993) Molecular aspects of tumor cell invasion and metastasis. Cancer 71:1368\u20131383","journal-title":"Cancer"},{"key":"469_CR17","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C","volume":"189","author":"S Curran","year":"1999","unstructured":"Curran S, Murray GI (1999) Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 189:300\u2013308","journal-title":"J Pathol"},{"key":"469_CR18","first-page":"4718","volume":"87","author":"DT Eitzman","year":"1996","unstructured":"Eitzman DT, Krauss JC, Shen T, Cui J, Ginsburg D (1996) Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 87:4718\u20134722","journal-title":"Blood"},{"key":"469_CR19","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","volume":"133","author":"S Paget","year":"1889","unstructured":"Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 133:571\u2013573","journal-title":"Lancet"},{"key":"469_CR20","first-page":"126","volume":"31","author":"VF Chekhun","year":"2009","unstructured":"Chekhun VF (2009) Stroma\u2014regulator of cancer cell progression. Exp Oncol 31:126","journal-title":"Exp Oncol"},{"key":"469_CR21","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/cdd.2009.206","volume":"17","author":"SP Cullen","year":"2010","unstructured":"Cullen SP, Brunet M, Martin SJ (2010) Granzymes in cancer and immunity. Cell Death Differ 17:616\u2013623","journal-title":"Cell Death Differ"},{"key":"469_CR22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.canlet.2008.04.006","volume":"268","author":"V Alla","year":"2008","unstructured":"Alla V, Kashyap A, Gregor S, Theobald M, Heid H, Galle PR, Strand D, Strand S (2008) Human leukocyte elastase counteracts matrix metalloproteinase-7 induced apoptosis resistance of tumor cells. Cancer Lett 268:331\u2013339","journal-title":"Cancer Lett"},{"key":"469_CR23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1152\/physiol.00027.2007","volume":"22","author":"N Sengupta","year":"2007","unstructured":"Sengupta N, MacDonald TT (2007) The role of matrix metalloproteinases in stromal\/epithelial interactions in the gut. Physiology (Bethesda) 22:401\u2013409","journal-title":"Physiology (Bethesda)"},{"key":"469_CR24","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3748\/wjg.v11.i9.1251","volume":"11","author":"E Skrzydlewska","year":"2005","unstructured":"Skrzydlewska E, Sulkowska M, Koda M, Sulkowski S (2005) Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. World J Gastroenterol 11:1251\u20131266","journal-title":"World J Gastroenterol"},{"key":"469_CR25","first-page":"151","volume":"378","author":"H Nagase","year":"1997","unstructured":"Nagase H (1997) Activation mechanisms of matrix metalloproteinases. Biol Chem 378:151\u2013160","journal-title":"Biol Chem"},{"key":"469_CR26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/cr.1998.18","volume":"8","author":"H Nagase","year":"1998","unstructured":"Nagase H (1998) Cell surface activation of progelatinase A (proMMP-2) and cell migration. Cell Res 8:179\u2013186","journal-title":"Cell Res"},{"key":"469_CR27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1387\/ijdb.041811af","volume":"48","author":"AR Folgueras","year":"2004","unstructured":"Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C (2004) Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 48:411\u2013424","journal-title":"Int J Dev Biol"},{"key":"469_CR28","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S0955-0674(98)80042-2","volume":"10","author":"RA Black","year":"1998","unstructured":"Black RA, White JM (1998) ADAMs: focus on the protease domain. Curr Opin Cell Biol 10:654\u2013659","journal-title":"Curr Opin Cell Biol"},{"key":"469_CR29","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0002-9440(10)65403-X","volume":"154","author":"K Iba","year":"1999","unstructured":"Iba K, Albrechtsen R, Gilpin BJ, Loechel F, Wewer UM (1999) Cysteine-rich domain of human ADAM 12 (meltrin alpha) supports tumor cell adhesion. Am J Pathol 154:1489\u20131501","journal-title":"Am J Pathol"},{"key":"469_CR30","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/01.ATV.0000209518.58252.17","volume":"26","author":"VW Hinsbergh van","year":"2006","unstructured":"van Hinsbergh VW, Engelse MA, Quax PH (2006) Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol 26:716\u2013728","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"469_CR31","doi-asserted-by":"crossref","first-page":"re6","DOI":"10.1126\/scisignal.127re6","volume":"1","author":"WG Stetler-Stevenson","year":"2008","unstructured":"Stetler-Stevenson WG (2008) Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 1:re6","journal-title":"Sci Signal"},{"key":"469_CR32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1699-0463.1999.tb01534.x","volume":"107","author":"K Dano","year":"1999","unstructured":"Dano K, Romer J, Nielsen BS, Bjorn S, Pyke C, Rygaard J, Lund LR (1999) Cancer invasion and tissue remodeling\u2013cooperation of protease systems and cell types. APMIS 107:120\u2013127","journal-title":"APMIS"},{"key":"469_CR33","first-page":"5683","volume":"54","author":"N Wernert","year":"1994","unstructured":"Wernert N, Gilles F, Fafeur V, Bouali F, Raes MB, Pyke C, Dupressoir T, Seitz G, Vandenbunder B, Stehelin D (1994) Stromal expression of c-Ets1 transcription factor correlates with tumor invasion. Cancer Res 54:5683\u20135688","journal-title":"Cancer Res"},{"key":"469_CR34","doi-asserted-by":"crossref","first-page":"10862","DOI":"10.1158\/0008-5472.CAN-05-1231","volume":"65","author":"KL Andarawewa","year":"2005","unstructured":"Andarawewa KL, Motrescu ER, Chenard MP, Gansmuller A, Stoll I, Tomasetto C, Rio MC (2005) Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction\/crosstalk at the tumor invasive front. Cancer Res 65:10862\u201310871","journal-title":"Cancer Res"},{"key":"469_CR35","first-page":"101","volume":"2","author":"J-Y Shih","year":"2006","unstructured":"Shih J-Y, Yuan A, Chen JJ-W, Yang P-C (2006) Tumor-associated macrophage: its role in cancer invasion and metastasis. J Cancer Mol 2:101\u2013106","journal-title":"J Cancer Mol"},{"key":"469_CR36","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/sj.onc.1209663","volume":"25","author":"W Cruz-Munoz","year":"2006","unstructured":"Cruz-Munoz W, Kim I, Khokha R (2006) TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis. Oncogene 25:650\u2013655","journal-title":"Oncogene"},{"key":"469_CR37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1523-1747.2000.00068.x","volume":"115","author":"UB Hofmann","year":"2000","unstructured":"Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ (2000) Matrix metalloproteinases in human melanoma. J Invest Dermatol 115:337\u2013344","journal-title":"J Invest Dermatol"},{"key":"469_CR38","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/ijc.1636","volume":"97","author":"J Nikkola","year":"2002","unstructured":"Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kahari VM, Pyrhonen S (2002) High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer 97:432\u2013438","journal-title":"Int J Cancer"},{"key":"469_CR39","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH632>3.0.CO;2-#","volume":"191","author":"UB Hofmann","year":"2000","unstructured":"Hofmann UB, Westphal JR, Zendman AJ, Becker JC, Ruiter DJ, van Muijen GN (2000) Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol 191:245\u2013256","journal-title":"J Pathol"},{"key":"469_CR40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/(SICI)1096-9896(199611)180:3<283::AID-PATH662>3.0.CO;2-3","volume":"180","author":"A Vaisanen","year":"1996","unstructured":"Vaisanen A, Tuominen H, Kallioinen M, Turpeenniemi-Hujanen T (1996) Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 180:283\u2013289","journal-title":"J Pathol"},{"key":"469_CR41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/(SICI)1096-9896(199809)186:1<51::AID-PATH131>3.0.CO;2-P","volume":"186","author":"A Vaisanen","year":"1998","unstructured":"Vaisanen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T (1998) Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 186:51\u201358","journal-title":"J Pathol"},{"key":"469_CR42","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/j.1460-2075.1995.tb07072.x","volume":"14","author":"JM Ray","year":"1995","unstructured":"Ray JM, Stetler-Stevenson WG (1995) Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J 14:908\u2013917","journal-title":"EMBO J"},{"key":"469_CR43","first-page":"8221","volume":"63","author":"UB Hofmann","year":"2003","unstructured":"Hofmann UB, Eggert AA, Blass K, Brocker EB, Becker JC (2003) Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer Res 63:8221\u20138225","journal-title":"Cancer Res"},{"key":"469_CR44","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/172460080502000407","volume":"20","author":"MD Corte","year":"2005","unstructured":"Corte MD, Gonzalez LO, Corte MG, Quintela I, Pidal I, Bongera M, Vizoso F (2005) Collagenase-3 (MMP-13) expression in cutaneous malignant melanoma. Int J Biol Markers 20:242\u2013248","journal-title":"Int J Biol Markers"},{"key":"469_CR45","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1038\/jid.2009.130","volume":"129","author":"P Zigrino","year":"2009","unstructured":"Zigrino P, Kuhn I, Bauerle T, Zamek J, Fox JW, Neumann S, Licht A, Schorpp-Kistner M, Angel P, Mauch C (2009) Stromal expression of MMP-13 is required for melanoma invasion and metastasis. J Invest Dermatol 129:2686\u20132693","journal-title":"J Invest Dermatol"},{"key":"469_CR46","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00428-005-0046-8","volume":"447","author":"T Kuivanen","year":"2005","unstructured":"Kuivanen T, Ahokas K, Virolainen S, Jahkola T, Holtta E, Saksela O, Saarialho-Kere U (2005) MMP-21 is upregulated at early stages of melanoma progression but disappears with more aggressive phenotype. Virchows Arch 447:954\u2013960","journal-title":"Virchows Arch"},{"key":"469_CR47","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.5732\/cjc.008.10768","volume":"28","author":"YG Zhao","year":"2009","unstructured":"Zhao YG, Xiao AZ, Ni J, Man YG, Sang QX (2009) Expression of matrix metalloproteinase-26 in multiple human cancer tissues and smooth muscle cells. Chin J Cancer 28:1168\u20131175","journal-title":"Chin J Cancer"},{"key":"469_CR48","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00008390-200206000-00007","volume":"12","author":"J Kanitakis","year":"2002","unstructured":"Kanitakis J, Narvaez D, Claudy A (2002) Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin. Melanoma Res 12:241\u2013244","journal-title":"Melanoma Res"},{"key":"469_CR49","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ijc.21087","volume":"116","author":"P Zigrino","year":"2005","unstructured":"Zigrino P, Mauch C, Fox JW, Nischt R (2005) Adam-9 expression and regulation in human skin melanoma and melanoma cell lines. Int J Cancer 116:853\u2013859","journal-title":"Int J Cancer"},{"key":"469_CR50","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1158\/0008-5472.CAN-07-5154","volume":"68","author":"A Gutierrez-Fernandez","year":"2008","unstructured":"Gutierrez-Fernandez A, Fueyo A, Folgueras AR, Garabaya C, Pennington CJ, Pilgrim S, Edwards DR, Holliday DL, Jones JL, Span PN, Sweep FC, Puente XS, Lopez-Otin C (2008) Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res 68:2755\u20132763","journal-title":"Cancer Res"},{"key":"469_CR51","first-page":"665","volume":"151","author":"JJ Oord van den","year":"1997","unstructured":"van den Oord JJ, Paemen L, Opdenakker G, de Wolf-Peeters C (1997) Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 151:665\u2013670","journal-title":"Am J Pathol"},{"key":"469_CR52","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2350-8-10","volume":"8","author":"J Cotignola","year":"2007","unstructured":"Cotignola J, Reva B, Mitra N, Ishill N, Chuai S, Patel A, Shah S, Vanderbeek G, Coit D, Busam K, Halpern A, Houghton A, Sander C, Berwick M, Orlow I (2007) Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma. BMC Med Genet 8:10","journal-title":"BMC Med Genet"},{"key":"469_CR53","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.lfs.2004.06.031","volume":"76","author":"PV Leyon","year":"2005","unstructured":"Leyon PV, Lini CC, Kuttan G (2005) Inhibitory effect of Boerhaavia diffusa on experimental metastasis by B16F10 melanoma in C57BL\/6 mice. Life Sci 76:1339\u20131349","journal-title":"Life Sci"},{"key":"469_CR54","first-page":"4174","volume":"55","author":"JR MacDougall","year":"1995","unstructured":"MacDougall JR, Bani MR, Lin Y, Rak J, Kerbel RS (1995) The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells. Cancer Res 55:4174\u20134181","journal-title":"Cancer Res"},{"key":"469_CR55","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10585-007-9136-0","volume":"25","author":"C Marconi","year":"2008","unstructured":"Marconi C, Bianchini F, Mannini A, Mugnai G, Ruggieri S, Calorini L (2008) Tumoral and macrophage uPAR and MMP-9 contribute to the invasiveness of B16 murine melanoma cells. Clin Exp Metastasis 25:225\u2013231","journal-title":"Clin Exp Metastasis"},{"key":"469_CR56","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1158\/0008-5472.CAN-04-0297","volume":"66","author":"AM Houghton","year":"2006","unstructured":"Houghton AM, Grisolano JL, Baumann ML, Kobayashi DK, Hautamaki RD, Nehring LC, Cornelius LA, Shapiro SD (2006) Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res 66:6149\u20136155","journal-title":"Cancer Res"},{"key":"469_CR57","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/sj.bjc.6690417","volume":"80","author":"K Airola","year":"1999","unstructured":"Airola K, Karonen T, Vaalamo M, Lehti K, Lohi J, Kariniemi AL, Keski-Oja J, Saarialho-Kere UK (1999) Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer 80:733\u2013743","journal-title":"Br J Cancer"},{"key":"469_CR58","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1006\/excr.1996.0117","volume":"224","author":"JA Nemeth","year":"1996","unstructured":"Nemeth JA, Rafe A, Steiner M, Goolsby CL (1996) TIMP-2 growth-stimulatory activity: a concentration- and cell type-specific response in the presence of insulin. Exp Cell Res 224:110\u2013115","journal-title":"Exp Cell Res"},{"key":"469_CR59","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2133.2006.07678.x","volume":"156","author":"K Kawasaki","year":"2007","unstructured":"Kawasaki K, Kawakami T, Watabe H, Itoh F, Mizoguchi M, Soma Y (2007) Expression of matrilysin (matrix metalloproteinase-7) in primary cutaneous and metastatic melanoma. Br J Dermatol 156:613\u2013619","journal-title":"Br J Dermatol"},{"key":"469_CR60","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/CMR.0b013e3283090031","volume":"18","author":"P Vihinen","year":"2008","unstructured":"Vihinen P, Koskivuo I, Syrjanen K, Tervahartiala T, Sorsa T, Pyrhonen S (2008) Serum matrix metalloproteinase-8 is associated with ulceration and vascular invasion of malignant melanoma. Melanoma Res 18:268\u2013273","journal-title":"Melanoma Res"},{"key":"469_CR61","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/ng.340","volume":"41","author":"LH Palavalli","year":"2009","unstructured":"Palavalli LH, Prickett TD, Wunderlich JR, Wei X, Burrell AS, Porter-Gill P, Davis S, Wang C, Cronin JC, Agrawal NS, Lin JC, Westbroek W, Hoogstraten-Miller S, Molinolo AA, Fetsch P, Filie AC, O\u2019Connell MP, Banister CE, Howard JD, Buckhaults P, Weeraratna AT, Brody LC, Rosenberg SA, Samuels Y (2009) Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet 41:518\u2013520","journal-title":"Nat Genet"},{"key":"469_CR62","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1385\/MO:22:1:039","volume":"22","author":"F Tas","year":"2005","unstructured":"Tas F, Duranyildiz D, Oguz H, Disci R, Kurul S, Yasasever V, Topuz E (2005) Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma. Med Oncol 22:39\u201344","journal-title":"Med Oncol"},{"key":"469_CR63","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/jnci\/djp038","volume":"101","author":"BE Gould Rothberg","year":"2009","unstructured":"Gould Rothberg BE, Bracken MB, Rimm DL (2009) Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 101:452\u2013474","journal-title":"J Natl Cancer Inst"},{"key":"469_CR64","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cca.2005.10.029","volume":"367","author":"AK Bosserhoff","year":"2006","unstructured":"Bosserhoff AK (2006) Novel biomarkers in malignant melanoma. Clin Chim Acta 367:28\u201335","journal-title":"Clin Chim Acta"},{"key":"469_CR65","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1248\/bpb.20.843","volume":"20","author":"T Oku","year":"1997","unstructured":"Oku T, Ata N, Yonezawa K, Tokai H, Fujii H, Shinagawa A, Ohuchi E, Saiki I (1997) Antimetastatic and antitumor effect of a recombinant human tissue inhibitor of metalloproteinases-2 in murine melanoma models. Biol Pharm Bull 20:843\u2013849","journal-title":"Biol Pharm Bull"},{"key":"469_CR66","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1749-6632.1999.tb07689.x","volume":"878","author":"DR Shalinsky","year":"1999","unstructured":"Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Truitt G, Wood A, Varki NM, Appelt K (1999) Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann NY Acad Sci 878:236\u2013270","journal-title":"Ann NY Acad Sci"},{"key":"469_CR67","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1023\/A:1020625423524","volume":"20","author":"I Quirt","year":"2002","unstructured":"Quirt I, Bodurth A, Lohmann R, Rusthoven J, Belanger K, Young V, Wainman N, Stewar W, Eisenhauer E (2002) Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 20:431\u2013437","journal-title":"Invest New Drugs"},{"key":"469_CR68","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ctrv.2007.10.005","volume":"34","author":"K Dass","year":"2008","unstructured":"Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH (2008) Evolving role of uPA\/uPAR system in human cancers. Cancer Treat Rev 34:122\u2013136","journal-title":"Cancer Treat Rev"},{"key":"469_CR69","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0065-230X(08)60028-7","volume":"44","author":"K Dan\u00f8","year":"1985","unstructured":"Dan\u00f8 K, Andreasen PA, Gr\u00f8ndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L (1985) Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44:139\u2013266","journal-title":"Adv Cancer Res"},{"key":"469_CR70","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1515\/bchm3.1992.373.2.611","volume":"373","author":"M Schmitt","year":"1992","unstructured":"Schmitt M, J\u00e4nicke F, Moniwa N, Chucholowski N, Pache L, Graeff H (1992) Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe Seyler 373:611\u2013622","journal-title":"Biol Chem Hoppe Seyler"},{"key":"469_CR71","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0955-0674(00)00140-X","volume":"12","author":"L Ossowski","year":"2000","unstructured":"Ossowski L, Aguirre-Ghiso JA (2000) Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 12:613\u2013620","journal-title":"Curr Opin Cell Biol"},{"key":"469_CR72","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1699-0463.1999.tb01526.x","volume":"107","author":"DJ Loskutoff","year":"1999","unstructured":"Loskutoff DJ, Curriden SA, Hu G, Deng G (1999) Regulation of cell adhesion by PAI-1. APMIS 107:54\u201361","journal-title":"APMIS"},{"key":"469_CR73","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/jcp.2003.014472","volume":"57","author":"A Noel","year":"2004","unstructured":"Noel A, Maillard C, Rocks N, Jost M, Chabottaux V, Sounni NE, Maquoi E, Cataldo D, Foidart JM (2004) Membrane associated proteases and their inhibitors in tumour angiogenesis. J Clin Pathol 57:577\u2013584","journal-title":"J Clin Pathol"},{"key":"469_CR74","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nm0898-923","volume":"4","author":"K Bajou","year":"1998","unstructured":"Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM (1998) Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4:923\u2013928","journal-title":"Nat Med"},{"key":"469_CR75","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1067\/mob.2003.169","volume":"188","author":"EE Khin","year":"2003","unstructured":"Khin EE, Kikkawa F, Ino K, Kajiyama H, Suzuki T, Shibata K, Tamakoshi K, Nagasaka T, Mizutani S (2003) Dipeptidyl peptidase IV expression in endometrial endometrioid adenocarcinoma and its inverse correlation with tumor grade. Am J Obstet Gynecol 188:670\u2013676","journal-title":"Am J Obstet Gynecol"},{"key":"469_CR76","first-page":"2753","volume":"62","author":"H Kajiyama","year":"2002","unstructured":"Kajiyama H, Kikkawa F, Suzuki T, Shibata K, Ino K, Mizutani S (2002) Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma. Cancer Res 62:2753\u20132757","journal-title":"Cancer Res"},{"key":"469_CR77","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/ijc.2910640508","volume":"64","author":"T Tanaka","year":"1995","unstructured":"Tanaka T, Umeki K, Yamamoto I, Sakamoto F, Noguchi S, Ohtaki S (1995) CD26 (dipeptidyl peptidase IV\/DPP IV) as a novel molecular marker for differentiated thyroid carcinoma. Int J Cancer 64:326\u2013331","journal-title":"Int J Cancer"},{"key":"469_CR78","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/j.1939-4640.2000.tb02099.x","volume":"21","author":"MJ Wilson","year":"2000","unstructured":"Wilson MJ, Ruhland AR, Quast BJ, Reddy PK, Ewing SL, Sinha AA (2000) Dipeptidylpeptidase IV activities are elevated in prostate cancers and adjacent benign hyperplastic glands. J Androl 21:220\u2013226","journal-title":"J Androl"},{"key":"469_CR79","first-page":"635","volume":"10","author":"B Stabuc","year":"2003","unstructured":"Stabuc B, Markovic J, Bartenjev I, Vrhovec I, Medved U, Kocijancic B (2003) Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma. Oncol Rep 10:635\u2013639","journal-title":"Oncol Rep"},{"key":"469_CR80","first-page":"1270","volume":"48","author":"VJ Hearing","year":"1988","unstructured":"Hearing VJ, Law LW, Corti A, Appella E, Blasi F (1988) Modulation of metastatic potential by surface urokinase of murine melanoma cells. Cancer Res 48:1270\u20131278","journal-title":"Cancer Res"},{"key":"469_CR81","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0922-3371(90)90040-4","volume":"32","author":"B Sordat","year":"1990","unstructured":"Sordat B, Reiter L, Cajot JF (1990) Modulation of the malignant phenotype with the urokinase-type plasminogen activator and the type I plasminogen activator inhibitor. Cell Differ Dev 32:277\u2013285","journal-title":"Cell Differ Dev"},{"key":"469_CR82","first-page":"2428","volume":"56","author":"HY Min","year":"1996","unstructured":"Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, Rosenberg S (1996) Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 56:2428\u20132433","journal-title":"Cancer Res"},{"key":"469_CR83","first-page":"4547","volume":"54","author":"C Delbaldo","year":"1994","unstructured":"Delbaldo C, Masouye I, Saurat JH, Vassalli JD, Sappino AP (1994) Plasminogen activation in melanocytic neoplasia. Cancer Res 54:4547\u20134552","journal-title":"Cancer Res"},{"key":"469_CR84","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1023\/A:1011882421528","volume":"18","author":"TD Brooks","year":"2000","unstructured":"Brooks TD, Slomp J, Quax PH, De Bart AC, Spencer MT, Verheijen JH, Charlton PA (2000) Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro. Clin Exp Metastasis 18:445\u2013453","journal-title":"Clin Exp Metastasis"},{"key":"469_CR85","first-page":"65","volume":"213","author":"BM Mueller","year":"1996","unstructured":"Mueller BM (1996) Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. Curr Top Microbiol Immunol 213:65\u201380","journal-title":"Curr Top Microbiol Immunol"},{"key":"469_CR86","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1023\/A:1012532412896","volume":"132","author":"ES Gershtein","year":"2001","unstructured":"Gershtein ES, Medvedeva SV, Babkina IV, Kushlinskii NE, Trapeznikov NN (2001) Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms. Bull Exp Biol Med 132:670\u2013674","journal-title":"Bull Exp Biol Med"},{"key":"469_CR87","first-page":"70","volume":"144","author":"TJ Vries de","year":"1994","unstructured":"de Vries TJ, Quax PH, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, Weidle UH, Ruiter DJ, van Muijen GN (1994) Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 144:70\u201381","journal-title":"Am J Pathol"},{"key":"469_CR88","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jdermsci.2008.07.014","volume":"53","author":"E Fr\u00f6hlich","year":"2009","unstructured":"Fr\u00f6hlich E, Maier E, Mack AF, Garbe C (2009) Dipeptidyl peptidase II is not a marker for progression in melanoma. J Dermatol Sci 53:68\u201371","journal-title":"J Dermatol Sci"},{"key":"469_CR89","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1023\/A:1010930918055","volume":"18","author":"CL Pethiyagoda","year":"2000","unstructured":"Pethiyagoda CL, Welch DR, Fleming TP (2000) Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells. Clin Exp Metastasis 18:391\u2013400","journal-title":"Clin Exp Metastasis"},{"key":"469_CR90","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1046\/j.1365-2133.1998.02171.x","volume":"138","author":"JJ Oord Van den","year":"1998","unstructured":"Van den Oord JJ (1998) Expression of CD26\/dipeptidyl-peptidase IV in benign and malignant pigment-cell lesions of the skin. Br J Dermatol 138:615\u2013621","journal-title":"Br J Dermatol"},{"key":"469_CR91","first-page":"81","volume-title":"New Research Communications on tumor markers","author":"E Fr\u00f6hlich","year":"2008","unstructured":"Fr\u00f6hlich E, Kr\u00f6ber S (2008) Activity and expression of dipeptidyl peptidase IV and cathepsin H in human cutaneous melanoma compared to other common cancers. In: Sch\u00e4fer L, Richter E (eds) New Research Communications on tumor markers. Nova, New York, pp 81\u201390"},{"key":"469_CR92","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1600-0749.2007.00363.x","volume":"20","author":"AE Denk","year":"2007","unstructured":"Denk AE, Bettstetter M, Wild PJ, Hoek K, Bataille F, Dietmaier W, Bosserhoff AK (2007) Loss of maspin expression contributes to a more invasive potential in malignant melanoma. Pigment Cell Res 20:112\u2013119","journal-title":"Pigment Cell Res"},{"key":"469_CR93","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/147323000603400106","volume":"34","author":"P Vereecken","year":"2006","unstructured":"Vereecken P, Reynaert S, Lalmand MC, Zouaoui-Boudjeltia K, Heenen M, Van Den Heule B, Petein M (2006) Decreased immunoreactive maspin expression in intermediate thickness and thick primary melanoma lesions. J Int Med Res 34:52\u201357","journal-title":"J Int Med Res"},{"key":"469_CR94","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jaad.2009.01.018","volume":"60","author":"R Chua","year":"2009","unstructured":"Chua R, Setzer S, Govindarajan B, Sexton D, Cohen C, Arbiser JL (2009) Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma. J Am Acad Dermatol 60:758\u2013766","journal-title":"J Am Acad Dermatol"},{"key":"469_CR95","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/path.1167","volume":"198","author":"CM Ferrier","year":"2002","unstructured":"Ferrier CM, Van Geloof WL, Straatman H, Van De Molengraft FJ, Van Muijen GN, Ruiter DJ (2002) Spitz naevi may express components of the plasminogen activation system. J Pathol 198:92\u201399","journal-title":"J Pathol"},{"key":"469_CR96","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0361-090X(02)00002-8","volume":"26","author":"GS Hanekom","year":"2002","unstructured":"Hanekom GS, Stubbings HM, Kidson SH (2002) The active fraction of plasmatic plasminogen activator inhibitor type 1 as a possible indicator of increased risk for metastatic melanoma. Cancer Detect Prev 26:50\u201359","journal-title":"Cancer Detect Prev"},{"key":"469_CR97","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1177\/153537020422901102","volume":"229","author":"RP Czekay","year":"2004","unstructured":"Czekay RP, Loskutoff DJ (2004) Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp Biol Med (Maywood) 229:1090\u20131096","journal-title":"Exp Biol Med (Maywood)"},{"key":"469_CR98","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1177\/42.7.8014475","volume":"42","author":"E Spiess","year":"1994","unstructured":"Spiess E, Br\u00fcning A, Gack S, Ulbricht B, Spring H, Trefz G, Ebert W (1994) Cathepsin B activity in human lung tumor cell lines: ultrastructural localization, pH sensitivity, and inhibitor status at the cellular level. J Histochem Cytochem 42:917\u2013929","journal-title":"J Histochem Cytochem"},{"key":"469_CR99","first-page":"4070","volume":"60","author":"K Lorenzo","year":"2000","unstructured":"Lorenzo K, Ton P, Clark JL, Coulibaly S, Mach L (2000) Invasive properties of murine squamous carcinoma cells: secretion of matrix-degrading cathepsins is attributable to a deficiency in the mannose 6-phosphate\/insulin-like growth factor II receptor. Cancer Res 60:4070\u20134076","journal-title":"Cancer Res"},{"key":"469_CR100","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/sj.neo.7900116","volume":"2","author":"M Sameni","year":"2000","unstructured":"Sameni M, Moin K, Sloane BF (2000) Imaging proteolysis by living human breast cancer cells. Neoplasia 2:496\u2013504","journal-title":"Neoplasia"},{"key":"469_CR101","doi-asserted-by":"crossref","first-page":"32347","DOI":"10.1074\/jbc.273.48.32347","volume":"273","author":"P Garnero","year":"1998","unstructured":"Garnero P, Borel O, Byrjalsen I, Ferreras M, Drake FH, McQueney MS, Foged NT, Delmas PD, Delaisse JM (1998) The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 273:32347\u201332352","journal-title":"J Biol Chem"},{"key":"469_CR102","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1038\/sj.onc.1205745","volume":"21","author":"G Berchem","year":"2002","unstructured":"Berchem G, Glondu M, Gleizes M, Brouillet JP, Vignon F, Garcia M, Liaudet-Coopman E (2002) Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene 21:5951\u20135955","journal-title":"Oncogene"},{"key":"469_CR103","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0002-9440(10)63914-4","volume":"162","author":"M Wolf","year":"2003","unstructured":"Wolf M, Clark-Lewis I, Buri C, Langen H, Lis M, Mazzucchelli L (2003) Cathepsin D specifically cleaves the chemokines macrophage inflammatory protein-1 alpha, macrophage inflammatory protein-1 beta, and SLC that are expressed in human breast cancer. Am J Pathol 162:1183\u20131190","journal-title":"Am J Pathol"},{"key":"469_CR104","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1073\/pnas.92.9.3849","volume":"92","author":"VY Reddy","year":"1995","unstructured":"Reddy VY, Zhang QY, Weiss SJ (1995) Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. Proc Natl Acad Sci USA 92:3849\u20133853","journal-title":"Proc Natl Acad Sci USA"},{"key":"469_CR105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/978-1-4757-9613-1_33","volume-title":"Cellular peptidases in immune functions and diseases","author":"H Kirschke","year":"1997","unstructured":"Kirschke H (1997) Lysosomal cysteine peptidases and malignant tumours. In: Ansorge S, Langner J (eds) Cellular peptidases in immune functions and diseases. Plenum, New York, pp 253\u2013257"},{"key":"469_CR106","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1126\/science.7233209","volume":"212","author":"BF Sloane","year":"1981","unstructured":"Sloane BF, Dunn JR, Honn KV (1981) Lysosomal cathepsin B: correlation with metastatic potential. Science 212:1151\u20131153","journal-title":"Science"},{"key":"469_CR107","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/0006-291X(89)91755-5","volume":"164","author":"J Rozhin","year":"1989","unstructured":"Rozhin J, Wade RL, Honn KV, Sloane BF (1989) Membrane-associated cathepsin L: a role in metastasis of melanomas. Biochim Biophys Res Comm 164:556\u2013561","journal-title":"Biochim Biophys Res Comm"},{"key":"469_CR108","first-page":"259","volume":"53","author":"B Stabuc","year":"2006","unstructured":"Stabuc B, Mrevlje Z, Markovic J, Stabuc-Silih M (2006) Expression and prognostic significance of cathepsin L in early cutaneous malignant melanoma. Neoplasma 53:259\u2013262","journal-title":"Neoplasma"},{"key":"469_CR109","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1475-2867-7-8","volume":"7","author":"Z Yang","year":"2007","unstructured":"Yang Z, Cox JL (2007) Cathepsin L increases invasion and migration of B16 melanoma. Cancer Cell Int 7:8","journal-title":"Cancer Cell Int"},{"key":"469_CR110","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/j.1365-2133.1995.tb16941.x","volume":"132","author":"E Fr\u00f6hlich","year":"1995","unstructured":"Fr\u00f6hlich E, Schaumburg-Lever G, Klessen C (1995) Immunocytochemical and immunelectron microscopic demonstration of cathepsin B in human malignant melanoma. Br J Dermatol 132:867\u2013875","journal-title":"Br J Dermatol"},{"key":"469_CR111","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/dna.1993.12.299","volume":"12","author":"Q Gong","year":"1993","unstructured":"Gong Q, Chan SJ, Bajkowsky AS, Steiner DF, Frankfater A (1993) Characterization of the cathepsin B gene and multiple mRNAs in human tissues: evidence for alternative splicing of cathepsin B pre- mRNA. DNA Cell Biol 12:299\u2013309","journal-title":"DNA Cell Biol"},{"key":"469_CR112","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00008390-199201000-00005","volume":"1","author":"H Tsushima","year":"1992","unstructured":"Tsushima H, Hyodoh F, Yoshida E, Ueki A, Hopsu-Havu VK (1992) Inactive cathepsin B-like enzyme in human melanoma culture medium. Melanoma Res 1:341\u2013347","journal-title":"Melanoma Res"},{"key":"469_CR113","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/1097-0142(20010301)91:5<972::AID-CNCR1087>3.0.CO;2-Q","volume":"91","author":"E Fr\u00f6hlich","year":"2001","unstructured":"Fr\u00f6hlich E, Schlagenhauff B, M\u00f6hrle M, Weber E, Klessen C, Rassner G (2001) Activity, expression and transcription rate of the cathepsins B, D, H and L in cutaneous malignant melanoma. Cancer 91:972\u2013982","journal-title":"Cancer"},{"key":"469_CR114","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1515\/bchm.1998.379.8-9.1093","volume":"379","author":"K Moin","year":"1998","unstructured":"Moin K, Cao L, Day NA, Koblinski JE, Sloane BF (1998) Tumor cell membrane cathepsin B. Biol Chem 379:1093\u20131099","journal-title":"Biol Chem"},{"key":"469_CR115","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1073\/pnas.83.8.2483","volume":"83","author":"BF Sloane","year":"1986","unstructured":"Sloane BF, Rozhin J, Johnson K, Taylor H, Crissman JD, Honn KV (1986) Cathepsin B: association with plasma membrane in metastatic tumors. Proc Natl Acad Sci USA 83:2483\u20132487","journal-title":"Proc Natl Acad Sci USA"},{"key":"469_CR116","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00403-003-0449-9","volume":"295","author":"E Fr\u00f6hlich","year":"2004","unstructured":"Fr\u00f6hlich E, M\u00f6hrle M, Klessen C (2004) Cathepsins in basal cell carcinomas: activity, immunoreactivity and mRNA staining of the cathepsins B, D, H, and L. Arch Dermatol Res 295:411\u2013421","journal-title":"Arch Dermatol Res"},{"key":"469_CR117","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1515\/BC.2004.132","volume":"385","author":"C Jedeszko","year":"2004","unstructured":"Jedeszko C, Sloane BF (2004) Cysteine cathepsins in human cancer. Biol Chem 385:1017\u20131027","journal-title":"Biol Chem"},{"key":"469_CR118","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1515\/BC.2002.088","volume":"383","author":"N Sever","year":"2002","unstructured":"Sever N, Filipic M, Brzin J, Lah TT (2002) Effect of cysteine proteinase inhibitors on murine B16 melanoma cell invasion in vitro. Biol Chem 383:839\u2013842","journal-title":"Biol Chem"},{"key":"469_CR119","first-page":"6517","volume":"54","author":"J Rozhin","year":"1994","unstructured":"Rozhin J, Sameni M, Ziegler G, Sloane BF (1994) Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res 54:6517\u20136525","journal-title":"Cancer Res"},{"key":"469_CR120","first-page":"3493","volume":"61","author":"AM Szpaderska","year":"2001","unstructured":"Szpaderska AM, Frankfater A (2001) An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res 61:3493\u20133500","journal-title":"Cancer Res"},{"key":"469_CR121","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/0008-5472.CAN-03-1717","volume":"64","author":"N Rousselet","year":"2004","unstructured":"Rousselet N, Mills L, Jean D, Tellez C, Bar-Eli M, Frade R (2004) Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment. Cancer Res 64:146\u2013151","journal-title":"Cancer Res"},{"key":"469_CR122","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0625.1998.tb00297.x","volume":"7","author":"A Ulmer","year":"1998","unstructured":"Ulmer A, Korber V, Schmid H, Fierlbeck G (1998) Increased activity of cathepsin B in fibroblasts isolated from primary melanoma in comparison to fibroblasts from normal skin. Exp Dermatol 7:14\u201317","journal-title":"Exp Dermatol"},{"key":"469_CR123","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/1523-1747.ep12665371","volume":"104","author":"OL Podhajcer","year":"1995","unstructured":"Podhajcer OL, Bover L, Bravo AI, Ledda MF, Kairiyama C, Calb I, Guerra L, Capony F, Mordoh J (1995) Expression of cathepsin D in primary and metastatic human melanoma and dysplastic nevi. J Invest Dermatol 104:340\u2013344","journal-title":"J Invest Dermatol"},{"key":"469_CR124","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0344-0338(99)80030-2","volume":"195","author":"T Goldmann","year":"1999","unstructured":"Goldmann T, Suter L, Ribbert D, Otto F (1999) The expression of proteolytic enzymes at the dermal invading front of primary cutaneous melanoma predicts metastasis. Pathol Res Pract 195:171\u2013175","journal-title":"Pathol Res Pract"},{"key":"469_CR125","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s004030050012","volume":"292","author":"L Kozlowski","year":"2000","unstructured":"Kozlowski L, Wojtukiewicz MZ, Ostrowska H (2000) Cathepsin A activity in primary and metastatic human melanocytic tumors. Arch Dermatol Res 292:68\u201371","journal-title":"Arch Dermatol Res"},{"key":"469_CR126","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/jid.2008.63","volume":"128","author":"MJ Quintanilla-Dieck","year":"2008","unstructured":"Quintanilla-Dieck MJ, Codriansky K, Keady M, Bhawan J, Runger TM (2008) Cathepsin K in melanoma invasion. J Invest Dermatol 128:2281\u20132288","journal-title":"J Invest Dermatol"},{"key":"469_CR127","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1158\/0008-5472.CAN-07-2048","volume":"67","author":"T Kawakubo","year":"2007","unstructured":"Kawakubo T, Okamoto K, Iwata J, Shin M, Okamoto Y, Yasukochi A, Nakayama KI, Kadowaki T, Tsukuba T, Yamamoto K (2007) Cathepsin E prevents tumor growth and metastasis by catalyzing the proteolytic release of soluble TRAIL from tumor cell surface. Cancer Res 67:10869\u201310878","journal-title":"Cancer Res"},{"key":"469_CR128","first-page":"712","volume":"106","author":"H Tsushima","year":"1985","unstructured":"Tsushima H, Sumi H, Hamanaka K, Toki N, Sato H, Mihara H (1985) Cysteine protease inhibitors isolated from human malignant melanoma tissue. J Lab Clin Med 106:712\u2013717","journal-title":"J Lab Clin Med"},{"key":"469_CR129","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00008390-199201000-00004","volume":"1","author":"G Boike","year":"1992","unstructured":"Boike G, Lah T, Sloane BF, Rozhin J, Honn K, Guirguis R, Stracke ML, Liotta LA, Schiffmann E (1992) A possible role for cysteine proteinase and its inhibitors in motility of malignant melanoma and other tumour cells. Melanoma Res 1:333\u2013340","journal-title":"Melanoma Res"},{"key":"469_CR130","first-page":"1815","volume":"3","author":"J Kos","year":"1997","unstructured":"Kos J, Stabuc B, Schweiger A, Krasovec M, Cimerman N, Kopitar Jerala N, Vrhovec I (1997) Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. Clin Cancer Res 3:1815\u20131822","journal-title":"Clin Cancer Res"},{"key":"469_CR131","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF01262334","volume":"287","author":"A Yoshii","year":"1995","unstructured":"Yoshii A, Kageshita T, Tsushima H, Ono T (1995) Clinical relevance of cathepsin B-like enzyme activity and cysteine proteinase inhibitor in melanocytic tumours. Arch Dermatol Res 287:209\u2013213","journal-title":"Arch Dermatol Res"},{"key":"469_CR132","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1515\/BC.2008.115","volume":"389","author":"U Schurigt","year":"2008","unstructured":"Schurigt U, Sevenich L, Vannier C, Gajda M, Schwinde A, Werner F, Stahl A, von Elverfeldt D, Becker AK, Bogyo M, Peters C, Reinheckel T (2008) Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model. Biol Chem 389:1067\u20131074","journal-title":"Biol Chem"},{"key":"469_CR133","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1475-2867-5-14","volume":"5","author":"H Ervin","year":"2005","unstructured":"Ervin H, Cox JL (2005) Late stage inhibition of hematogenous melanoma metastasis by cystatin C over-expression. Cancer Cell Int 5:14","journal-title":"Cancer Cell Int"},{"key":"469_CR134","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.biocel.2007.11.007","volume":"40","author":"PA Konstantinopoulos","year":"2008","unstructured":"Konstantinopoulos PA, Karamouzis MV, Papatsoris AG, Papavassiliou AG (2008) Matrix metalloproteinase inhibitors as anticancer agents. Int J Biochem Cell Biol 40:1156\u20131168","journal-title":"Int J Biochem Cell Biol"},{"key":"469_CR135","first-page":"289","volume":"3","author":"CG Murphy","year":"2009","unstructured":"Murphy CG, Modi S (2009) HER2 breast cancer therapies: a review. Biologics 3:289\u2013301","journal-title":"Biologics"},{"key":"469_CR136","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/jnci\/djk065","volume":"99","author":"SA Williams","year":"2007","unstructured":"Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR (2007) A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst 99:376\u2013385","journal-title":"J Natl Cancer Inst"},{"key":"469_CR137","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1074\/jbc.M707419200","volume":"283","author":"S Liu","year":"2008","unstructured":"Liu S, Wang H, Currie BM, Molinolo A, Leung HJ, Moayeri M, Basile JR, Alfano RW, Gutkind JS, Frankel AE, Bugge TH, Leppla SH (2008) Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. J Biol Chem 283:529\u2013540","journal-title":"J Biol Chem"},{"key":"469_CR138","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/sj.bjp.0707657","volume":"153","author":"JM Atkinson","year":"2008","unstructured":"Atkinson JM, Siller CS, Gill JH (2008) Tumour endoproteases: the cutting edge of cancer drug delivery? Br J Pharmacol 153:1344\u20131352","journal-title":"Br J Pharmacol"},{"key":"469_CR139","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/(SICI)1097-0215(19990209)80:4<617::AID-IJC22>3.0.CO;2-C","volume":"80","author":"CH Graham","year":"1999","unstructured":"Graham CH, Forsdike J, Fitzgerald CJ, Macdonald-Goodfellow S (1999) Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer 80:617\u2013623","journal-title":"Int J Cancer"},{"key":"469_CR140","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/cgt.2008.51","volume":"15","author":"R Frade","year":"2008","unstructured":"Frade R, Rousselet N, Jean D (2008) Intratumoral gene delivery of anti-cathepsin L single-chain variable fragment by lentiviral vector inhibits tumor progression induced by human melanoma cells. Cancer Gene Ther 15:591\u2013604","journal-title":"Cancer Gene Ther"},{"key":"469_CR141","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.canlet.2006.08.016","volume":"249","author":"B Sun","year":"2007","unstructured":"Sun B, Zhang D, Zhang S, Zhang W, Guo H, Zhao X (2007) Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett 249:188\u2013197","journal-title":"Cancer Lett"},{"key":"469_CR142","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1002\/eji.200526262","volume":"35","author":"W Zhao","year":"2005","unstructured":"Zhao W, Darmanin S, Fu Q, Chen J, Cui H, Wang J, Okada F, Hamada J, Hattori Y, Kondo T, Hamuro J, Asaka M, Kobayashi M (2005) Hypoxia suppresses the production of matrix metalloproteinases and the migration of human monocyte-derived dendritic cells. Eur J Immunol 35:3468\u20133477","journal-title":"Eur J Immunol"},{"key":"469_CR143","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00280-009-0937-5","volume":"64","author":"K Miyake","year":"2009","unstructured":"Miyake K, Shimada M, Nishioka M, Sugimoto K, Batmunkh E, Uto Y, Nagasawa H, Hori H (2009) Downregulation of matrix metalloprotease-9 and urokinase plasminogen activator by TX-1877 results in decreased tumor growth and metastasis on xenograft model of rectal cancer. Cancer Chemother Pharmacol 64:885\u2013892","journal-title":"Cancer Chemother Pharmacol"},{"key":"469_CR144","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s11095-005-8343-0","volume":"22","author":"D Shenoy","year":"2005","unstructured":"Shenoy D, Little S, Langer R, Amiji M (2005) Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 2. In vivo distribution and tumor localization studies. Pharm Res 22:2107\u20132114","journal-title":"Pharm Res"},{"key":"469_CR145","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0928-0987(02)00257-9","volume":"18","author":"K Na","year":"2003","unstructured":"Na K, Bum Lee T, Park KH, Shin EK, Lee YB, Choi HK (2003) Self-assembled nanoparticles of hydrophobically-modified polysaccharide bearing vitamin H as a targeted anti-cancer drug delivery system. Eur J Pharm Sci 18:165\u2013173","journal-title":"Eur J Pharm Sci"},{"key":"469_CR146","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0168-3659(03)00205-0","volume":"90","author":"ES Lee","year":"2003","unstructured":"Lee ES, Shin HJ, Na K, Bae YH (2003) Poly(l-histidine)-PEG block copolymer micelles and pH-induced destabilization. J Control Release 90:363\u2013374","journal-title":"J Control Release"},{"key":"469_CR147","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/mp.52.6.332","volume":"52","author":"CG Huh","year":"1999","unstructured":"Huh CG, Hakansson K, Nathanson CM, Thorgeirsson UP, Jonsson N, Grubb A, Abrahamson M, Karlsson S (1999) Decreased metastatic spread in mice homozygous for a null allele of the cystatin C protease inhibitor gene. Mol Pathol 52:332\u2013340","journal-title":"Mol Pathol"},{"key":"469_CR148","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1007\/s002800170004","volume":"47(Suppl)","author":"M Wald","year":"2001","unstructured":"Wald M, Olejar T, Sebkova V, Zadinova M, Boubelik M, Pouckova P (2001) Mixture of trypsin, chymotrypsin and papain reduces formation of metastases and extends survival time of C57Bl6 mice with syngeneic melanoma B16. Cancer Chemother Pharmacol 47(Suppl):S16\u2013S22","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-010-0469-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00018-010-0469-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-010-0469-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T02:20:29Z","timestamp":1711678829000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00018-010-0469-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,5]]},"references-count":148,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["469"],"URL":"https:\/\/doi.org\/10.1007\/s00018-010-0469-5","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,5]]}}}